Clinical Trials Browser

NIH × Taxes × Genitourinary × Clear all

NCT06524544 2026-05-27

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT04579224 2026-05-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Phase 1/2 Completed

70 enrolled 10 charts

Bladder Urothelial Carcinoma

NCT00005831 2013-01-14

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Phase 2 Completed

Urinary Bladder Neoplasms